Crinetics Pharmaceuticals, Inc.

Bristol-Myers Squibb Compnay

Onxeo

Ian Yates

Corey Bloom

Clayton Tyler

Caroline Lemarchand

Xiaotian S Yin

Kyle Kyburz

Hannah Bulovsky

Gerald Burke

Sherif Ibrahim Farag Badawy

Perrine Pivette

Christoph Gesenberg

Candice Y Choi

Balvinder S Vig

Jonathan R Brown

John Wynne Jones

Christopher A Zordan

Vivienne Gray

Umesh Kestur

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

Dosage forms for Tyk2 inhibitors

Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Formulations of a somatostatin modulator

The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.

Oral formulations of belinostat

Growing community of inventors

Bend, OR, United States of America

Ian Yates